PUBLISHER: The Business Research Company | PRODUCT CODE: 1951749
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951749
Electrocompetent cells are bacterial cells specially treated to enhance their ability to take up foreign DNA through electroporation. Their membranes are made permeable by washing with a cold, ion-free solution, often containing glycerol or water. When exposed to a brief electric pulse, pores open in the membrane, allowing plasmid DNA to enter. These cells are commonly used in applications requiring high transformation efficiency in genetic engineering.
The main types of electrocompetent cells include bacterial, yeast, plant, and mammalian electrocompetent cells. Bacterial electrocompetent cells are engineered with permeable membranes to enable highly efficient DNA uptake during electroporation. Technologies used include electroporation and chemical transformation, with packaging formats such as tubes, plates, and custom options. These cells are applied in gene cloning, protein expression, transfection studies, gene editing, therapeutic research, and more. End users include pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs), and other related entities.
Tariffs have affected the electrocompetent cells market by increasing the cost of imported laboratory reagents, consumables, and specialized equipment used in cell preparation and electroporation. These impacts have been most visible in pharmaceutical and academic research segments in North America and Europe. Asia-Pacific suppliers have faced cost pressures due to reliance on imported biotech inputs. However, tariffs have encouraged local production of research reagents and strengthened domestic life sciences manufacturing capabilities.
The electrocompetent cells market research report is one of a series of new reports from The Business Research Company that provides electrocompetent cells market statistics, including electrocompetent cells industry global market size, regional shares, competitors with a electrocompetent cells market share, detailed electrocompetent cells market segments, market trends and opportunities, and any further data you may need to thrive in the electrocompetent cells industry. This electrocompetent cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The electrocompetent cells market size has grown strongly in recent years. It will grow from $1.57 billion in 2025 to $1.73 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to growth in molecular biology research, increased use of plasmid cloning, expansion of academic research institutes, rising demand for recombinant proteins, adoption of electroporation techniques.
The electrocompetent cells market size is expected to see strong growth in the next few years. It will grow to $2.51 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to growth of gene therapy research, rising crispr-based studies, expansion of biotechnology pipelines, increased outsourcing to cros, demand for high-throughput genetic engineering. Major trends in the forecast period include rising demand for high-efficiency transformation cells, growing use in gene editing applications, increasing adoption in synthetic biology research, expansion of custom and ready-to-use cell formats, rising utilization in therapeutic development.
The rising demand for genetic engineering is expected to propel the growth of the electrocompetent cells market going forward. Genetic engineering involves intentionally modifying an organism's genetic material to alter its traits or behavior. The increase in genetic engineering is driven by the need for higher agricultural productivity, enabling the development of crops with improved yields and pest resistance while reducing reliance on chemicals. This growing focus on genetic modifications fuels the demand for electrocompetent cells, which are essential for efficient DNA transformation. As applications expand across research, healthcare, and agriculture, the need for high-quality electrocompetent cells continues to rise. For instance, in April 2025, according to the Economic Research Service, a US-based government agency, genetically engineered, insect-resistant seeds were used on 90 percent of cotton acres in the U.S. Therefore, the rising demand for genetic engineering is driving the growth of the electrocompetent cells market.
Major companies operating in the electrocompetent cells market are focusing on developing advanced solutions, such as automated cell processing technology, to enhance scalability in genetic engineering workflows. Automated cell processing technology uses software-driven systems to manage the handling, cultivation, modification, and preservation of cells with minimal manual intervention. This approach boosts operational efficiency, standardization, and scalability across applications such as cell therapy, regenerative medicine, and biomanufacturing. For instance, in 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, launched the Gibco Cell Therapy Systems (CTS) Cellmation Software, a validated automation solution designed to integrate workflows across multiple cell therapy instruments while maintaining cGMP compliance. The software connects core instruments, including the CTS DynaCellect Magnetic Separation System, CTS Rotea Counterflow Centrifugation System, CTS Xenon Electroporation System, Heracell Vios CR CO2 Incubator, and Cryomed Controlled-Rate Freezer, within a single user-friendly interface. By reducing manual touchpoints from an estimated 40 in traditional processes, it minimizes error and contamination risks while ensuring traceability, repeatability, and 21 CFR Part 11 compliance for scaling cGMP manufacturing processes.
In January 2024, MaxCyte Inc., a US-based provider of electroporation systems, partnered with Wugen Inc. to advance innovative cancer therapies using scalable cell engineering technology. The partnership aims to accelerate the clinical and commercial manufacturing scale-up of Wugen's allogeneic, off-the-shelf cell therapies targeting hematologic and solid tumor cancers. By leveraging MaxCyte's high-efficiency and scalable cell engineering technology, the collaboration seeks to bring these therapies to patients with limited treatment options. Wugen Inc. is a US-based company specializing in the development of off-the-shelf cellular therapies for cancer.
Major companies operating in the electrocompetent cells market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Biosciences, Bio-Rad Laboratories Inc., Takara Bio Inc., Promega Corporation, New England Biolabs, OriGene Technologies, MaxCyte, LGC Biosearch Technologies, IBA GmbH, Zymo Research, Creative Biolabs, Inovio Pharmaceuticals Inc., Canvax, Yeastern Biotech, ZellBio GmbH, Scarab Genomics LLC, Intact Genomics.
North America was the largest region in the electrocompetent cells market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the electrocompetent cells market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the electrocompetent cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The electrocompetent cells market consists of revenues earned by entities by providing services such as custom strain development, plasmid DNA amplification, library construction, and technical support for molecular biology applications. The market value includes the value of related goods sold by the service provider or included within the service offering. The electrocompetent cells market includes sales of insect electrocompetent cells, fungal electrocompetent cells, and algal electrocompetent cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Electrocompetent Cells Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses electrocompetent cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for electrocompetent cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The electrocompetent cells market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.